Progestin-Primed Ovarian Stimulation Protocol for Patients in Assisted Reproductive Technology: A Meta-Analysis of Randomized Controlled Trials

Shaogen Guan, Yuezhi Feng, Yonghan Huang, Jia Huang, Shaogen Guan, Yuezhi Feng, Yonghan Huang, Jia Huang

Abstract

Objectives: Progestin-primed ovarian stimulation (PPOS) is a new ovarian stimulation protocol that can block the luteinizing hormone (LH) surge through progesterone instead of traditional down regulating or gonadotropin-releasing hormone (GnRH) antagonist, and in order to achieve multi-follicle recruitment. This paper aims to investigate the effectiveness of PPOS and its suitability for infertile patients with different ovarian reserve functions.

Methods: We searched published randomized controlled trials (RCTs) about PPOS on Cochrane Library, PubMed, Embase, and Web of Science. The search period spanned from January 1, 2015 to November 16, 2020. The data were extracted, and the meta-analysis was performed on ovarian stimulation as well as embryological and clinical outcomes. The outcomes were pooled by a random effects model, and the risk of heterogeneity was evaluated. Subgroup analysis was performed for different ovarian reserve patients.

Results: The clinical pregnancy rates and live birth or ongoing pregnancy rates with the PPOS protocol were not different from those with the control group. In the diminished ovarian reserve (DOR) subgroup, the PPOS protocol had a lower rate of premature LH surge [RR = 0.03, 95% CI = 0.01 to 0.13, p < 0.001]. The PPOS protocol had a lower rate of ovarian hyperstimulation syndrome (OHSS) [RR = 0.52, 95% CI = 0.36 to 0.76, p < 0.001, I2 = 0.00%]. The secondary outcomes showed that the number of oocytes retrieved, MII oocytes, and viable embryos was higher than that of the control protocol in DOR patients [(MD = 0.33, 95% CI = 0.30 to 0.36, p < 0.001), (MD = 0.30, 95% CI = 0.27 to 0.33, p < 0.001), (MD = 0.21, 95% CI = 0.18 to 0.24, p < 0.001)] and normal ovarian reserve (NOR) patients [(MD = 1.41, 95% CI = 0.03 to 2.78, p < 0.001), (MD = 1.19, 95% CI = 0.04 to 2.35, p < 0.001), (MD = 1.01, 95% CI = 0.21 to 1.81, p = 0.01)].

Conclusion: The findings suggest that PPOS is an effective ovarian stimulation protocol and is beneficial for patients with different ovarian reserve functions, which needs to be validated in more RCTs with larger samples.

Keywords: assisted reproductive technology; ovarian hyperstimulation syndrome; ovarian stimulation; pregnancy outcome; premature LH surge; progesterone; progestin-primed ovarian stimulation.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Guan, Feng, Huang and Huang.

Figures

Figure 1
Figure 1
PRISMA flow diagram of study selection for the systematic review and meta-analysis.
Figure 2
Figure 2
Risk of bias assessment for the randomized studies.
Figure 3
Figure 3
Forest plot of studies of premature LH surge.
Figure 4
Figure 4
Forest plot of studies of clinical pregnancy rate per woman.
Figure 5
Figure 5
Forest plot of studies of live birth or ongoing pregnancy rate per woman.
Figure 6
Figure 6
Forest plot of studies of OHSS.

References

    1. Andersen AN, Gianaroli L, Felberbaum R, de Mouzon J, Nygren KG, European Ivf-monitoring programme E.S.o.H.R, et al. . Assisted Reproductive Technology in Europe, 2001. Results Gecnerated from European Registers by ESHRE. Hum Reprod (2005) 20:1158–76. 10.1093/humrep/deh755
    1. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. . Prospective, Randomized, Controlled Study of In Vitro Fertilization-Embryo Transfer With a Single Dose of a Luteinizing Hormone-Releasing Hormone (LH-RH) Antagonist (Cetrorelix) or a Depot Formula of an LH-RH Agonist (Triptorelin). Fertil Steril (2000) 73:314–20. 10.1016/s0015-0282(99)00524-5
    1. Westergaard LG, Erb K, Laursen SB, Rex S, Rasmussen PE. Human Menopausal Gonadotropin Versus Recombinant Follicle-Stimulating Hormone in Normogonadotropic Women Down-Regulated With a Gonadotropin-Releasing Hormone Agonist Who Were Undergoing In Vitro Fertilization and Intracytoplasmic Sperm Injection: A Prospective Randomized Study. Fertil Steril (2001) 76:543–9. 10.1016/s0015-0282(01)01973-2
    1. Messinis IE. Ovarian Feedback, Mechanism of Action and Possible Clinical Implications. Hum Reprod Update (2006) 12:557–71. 10.1093/humupd/dml020
    1. Papanikolaou EG, Kolibianakis EM, Pozzobon C, Tank P, Tournaye H, Bourgain C, et al. . Progesterone Rise on the Day of Human Chorionic Gonadotropin Administration Impairs Pregnancy Outcome in Day 3 Single-Embryo Transfer, While has No Effect on Day 5 Single Blastocyst Transfer. Fertil Steril (2009) 91:949–52. 10.1016/j.fertnstert.2006.12.064
    1. Labarta E, Martínez-Conejero JA, Alamá P, Horcajadas JA, Pellicer A, Simón C, et al. . Endometrial Receptivity Is Affected in Women With High Circulating Progesterone Levels at the End of the Follicular Phase: A Functional Genomics Analysis. Hum Reprod (2011) 26:1813–25. 10.1093/humrep/der126
    1. Van Vaerenbergh I, Fatemi HM, Blockeel C, Van Lommel L, In't Veld P, Schuit F, et al. . Progesterone Rise on HCG Day in GnRH Antagonist/rFSH Stimulated Cycles Affects Endometrial Gene Expression. Reprod BioMed Online (2011) 22:263–71. 10.1016/j.rbmo.2010.11.002
    1. Droesch K, Muasher SJ, Brzyski RG, Jones GS, Simonetti S, Liu HC, et al. . Value of Suppression With a Gonadotropin-Releasing Hormone Agonist Prior to Gonadotropin Stimulation for In Vitro Fertilization. Fertil Steril (1989) 51:292–7. 10.1016/s0015-0282(16)60493-4
    1. van Loenen AC, Huirne JA, Schats R, Hompes PG, Lambalk CB. GnRH Agonists, Antagonists, and Assisted Conception. Semin Reprod Med (2002) 20:349–64. 10.1055/s-2002-36713
    1. Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-Releasing Hormone Antagonists for Assisted Reproductive Technology. Cochrane Database Syst Rev (2016) 4:CD001750. 10.1002/14651858.CD001750.pub4
    1. Toftager M, Bogstad J, Bryndorf T, Lossl K, Roskaer J, Holland T, et al. . Risk of Severe Ovarian Hyperstimulation Syndrome in GnRH Antagonist Versus GnRH Agonist Protocol: RCT Including 1050 First IVF/ICSI Cycles. Hum Reprod (2016) 31:1253–64. 10.1093/humrep/dew051
    1. Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. Ovarian Hyperstimulation Syndrome Prevention by Gonadotropin-Releasing Hormone Agonist Triggering of Final Oocyte Maturation in a Gonadotropin-Releasing Hormone Antagonist Protocol in Combination With a "Freeze-All" Strategy: A Prospective Multicentric Study. Fertil Steril (2011) 95:2029–33, 2033.e2021. 10.1016/j.fertnstert.2011.01.163
    1. Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. . Medroxyprogesterone Acetate is an Effective Oral Alternative for Preventing Premature Luteinizing Hormone Surges in Women Undergoing Controlled Ovarian Hyperstimulation for In Vitro Fertilization. Fertil Steril (2015) 104:62–70. e63. 10.1016/j.fertnstert.2015.03.022
    1. Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial. Medicine (Baltimore) (2016) 95:e2939. 10.1097/md.0000000000002939
    1. Zhu X, Ye H, Fu Y. The Utrogestan and hMG Protocol in Patients With Polycystic Ovarian Syndrome Undergoing Controlled Ovarian Hyperstimulation During IVF/ICSI Treatments. Medicine (United States) (2016) 95(28):e4193. 10.1097/MD.0000000000004193
    1. Massin N. New Stimulation Regimens: Endogenous and Exogenous Progesterone Use to Block the LH Surge During Ovarian Stimulation for IVF. Hum Reprod Update (2017) 23:211–20. 10.1093/humupd/dmw047
    1. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. . The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials. BMJ (2011) 343:d5928. 10.1136/bmj.d5928
    1. Cheung MW, Vijayakumar R. A Guide to Conducting a Meta-Analysis. Neuropsychol Rev (2016) 26:121–8. 10.1007/s11065-016-9319-z
    1. Chen Q, Wang Y, Sun L, Zhang S, Chai W, Hong Q, et al. . Controlled Ovulation of the Dominant Follicle Using Progestin in Minimal Stimulation in Poor Responders. Reprod Biol Endocrinol (2017) 15:71. 10.1186/s12958-017-0291-0
    1. Chen Q, Chai W, Wang Y, Cai R, Zhang S, Lu X, et al. . Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing In Vitro Fertilization Treatment: A Randomized Controlled Trial. Front Endocrinol (Lausanne) (2019) 10:796. 10.3389/fendo.2019.00796
    1. Eftekhar M, Hoseini M, Saeed L. Progesterone-Primed Ovarian Stimulation in Polycystic Ovarian Syndrome: An RCT. Int J Reprod Biomed (2019) 17:671–6. 10.18502/ijrm.v17i9.5103
    1. Ghasemzadeh A, Dopour Faliz M, Farzadi L, Navali N, Bahramzadeh B, Fadavi A, et al. . Effect of Oral Utrogestan in Comparison With Cetrotide on Preventing Luteinizing Hormone Surge in IVF Cycles: A Randomized Controlled Trial. Int J Reprod Biomed (2019) 18:41–6. 10.18502/ijrm.v18i1.6197
    1. Hossein Rashidi B, Tarafdari A, Ghazimirsaeed ST, Shahrokh Tehraninezhad E, Keikha F, Eslami B, et al. . Comparison of Dydrogesterone and GnRH Antagonists for Prevention of Premature LH Surge in IVF/ICSI Cycles: A Randomized Controlled Trial. J Family Reprod Health (2020) 14:14–20.
    1. Iwami N, Kawamata M, Ozawa N, Yamamoto T, Watanabe E, Moriwaka O, et al. . New Trial of Progestin-Primed Ovarian Stimulation Using Dydrogesterone Versus a Typical GnRH Antagonist Regimen in Assisted Reproductive Technology. Arch Gynecol Obstet (2018) 298:663–71. 10.1007/s00404-018-4856-8
    1. Xi Q, Tao Y, Qiu M, Wang Y, Kuang Y. Comparison Between PPOS and GnRHa-Long Protocol in Clinical Outcome With the First IVF/ICSI Cycle: A Randomized Clinical Trial. Clin Epidemiol (2020) 12:261–72. 10.2147/clep.S226414
    1. Alexandru P, Cekic SG, Yildiz S, Turkgeldi E, Ata B. Progestins Versuss GnRH Analogues for Pituitary Suppression During Ovarian Stimulation for Assisted Reproductive Technology: A Systematic Review and Meta-Analysis. Reprod BioMed Online (2020) 40:894–903. 10.1016/j.rbmo.2020.01.027
    1. Wu YG, Barad DH, Kushnir VA, Lazzaroni E, Wang Q, Albertini DF, et al. . Aging-Related Premature Luteinization of Granulosa Cells Is Avoided by Early Oocyte Retrieval. J Endocrinol (2015) 226:167–80. 10.1530/joe-15-0246
    1. Reichman DE, Zakarin L, Chao K, Meyer L, Davis OK, Rosenwaks Z. Diminished Ovarian Reserve Is the Predominant Risk Factor for Gonadotropin-Releasing Hormone Antagonist Failure Resulting in Breakthrough Luteinizing Hormone Surges in In Vitro Fertilization Cycles. Fertil Steril (2014) 102:99–102. 10.1016/j.fertnstert.2014.04.010
    1. Albano C, Felberbaum RE, Smitz J, Riethmüller-Winzen H, Engel J, Diedrich K, et al. . Ovarian Stimulation With HMG: Results of a Prospective Randomized Phase III European Study Comparing the Luteinizing Hormone-Releasing Hormone (LHRH)-Antagonist Cetrorelix and the LHRH-Agonist Buserelin. Eur Cetrorelix Study Group. Hum Reprod (2000) 15:526–31. 10.1093/humrep/15.3.526
    1. Messinis IE, Loutradis D, Domali E, Kotsovassilis CP, Papastergiopoulou L, Kallitsaris A, et al. . Alternate Day and Daily Administration of GnRH Antagonist may Prevent Premature Luteinization to a Similar Extent During FSH Treatment. Hum Reprod (2005) 20:3192–7. 10.1093/humrep/dei210
    1. Mansour RT, Aboulghar MA, Serour GI, Al-Inany HG, Amin YM, Abou-Setta AM. The Use of Gonadotropin-Releasing Hormone Antagonist in a Flexible Protocol: A Pilot Study. Am J Obstet Gynecol (2003) 189:444–6. 10.1067/s0002-9378(03)00489-7
    1. Dierschke DJ, Yamaji T, Karsch FJ, Weick RF, Weiss G, Knobil E. Blockade by Progesterone of Estrogen-Induced LH and FSH Release in the Rhesus Monkey. Endocrinology (1973) 92:1496–501. 10.1210/endo-92-5-1496
    1. Attardi B, Scott R, Pfaff D, Fink G. Facilitation or Inhibition of the Oestradiol-Induced Gonadotrophin Surge in the Immature Female Rat by Progesterone: Effects on Pituitary Responsiveness to Gonadotrophin-Releasing Hormone (GnRH), GnRH Self-Priming and Pituitary mRNAs for the Progesterone Receptor A and B Isoforms. J Neuroendocrinol (2007) 19:988–1000. 10.1111/j.1365-2826.2007.01613.x
    1. Kasa-Vubu JZ, Dahl GE, Evans NP, Thrun LA, Moenter SM, Padmanabhan V, et al. . Progesterone Blocks the Estradiol-Induced Gonadotropin Discharge in the Ewe by Inhibiting the Surge of Gonadotropin-Releasing Hormone. Endocrinology (1992) 131:208–12. 10.1210/endo.131.1.1611998
    1. Evans NP, Richter TA, Skinner DC, Robinson JE. Neuroendocrine Mechanisms Underlying the Effects of Progesterone on the Oestradiol-Induced GnRH/LH Surge. Reprod (2002) Suppl. 59:57–66.
    1. Heikinheimo O, Gordon K, Williams RF, Hodgen GD. Inhibition of Ovulation by Progestin Analogs (Agonists vs Antagonists): Preliminary Evidence for Different Sites and Mechanisms of Actions. Contraception (1996) 53:55–64. 10.1016/0010-7824(95)00255-3
    1. Soules MR, Steiner RA, Clifton DK, Cohen NL, Aksel S, Bremner WJ. Progesterone Modulation of Pulsatile Luteinizing Hormone Secretion in Normal Women. J Clin Endocrinol Metab (1984) 58:378–83. 10.1210/jcem-58-2-378
    1. Harris TG, Dye S, Robinson JE, Skinner DC, Evans NP. Progesterone can Block Transmission of the Estradiol-Induced Signal for Luteinizing Hormone Surge Generation During a Specific Period of Time Immediately After Activation of the Gonadotropin-Releasing Hormone Surge-Generating System. Endocrinology (1999) 140:827–34. 10.1210/endo.140.2.6490
    1. Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, et al. . Luteal-Phase Ovarian Stimulation Is Feasible for Producing Competent Oocytes in Women Undergoing In Vitro Fertilization/Intracytoplasmic Sperm Injection Treatment, With Optimal Pregnancy Outcomes in Frozen-Thawed Embryo Transfer Cycles. Fertil Steril (2014) 101:105–11. 10.1016/j.fertnstert.2013.09.007
    1. Bu Z, Zhao F, Wang K, Guo Y, Su Y, Zhai J, et al. . Serum Progesterone Elevation Adversely Affects Cumulative Live Birth Rate in Different Ovarian Responders During In Vitro Fertilization and Embryo Transfer: A Large Retrospective Study. PloS One (2014) 9:e100011. 10.1371/journal.pone.0100011
    1. La Marca A, Capuzzo M, Sacchi S, Imbrogno MG, Spinella F, Varricchio MT, et al. . Comparison of Euploidy Rates of Blastocysts in Women Treated With Progestins or GnRH Antagonist to Prevent the Luteinizing Hormone Surge During Ovarian Stimulation. Hum Reprod (2020) 35:1325–31. 10.1093/humrep/deaa068
    1. Huang JY, Xie Q, Lin JY, Lu XF, Wang NL, Gao HY, et al. . Neonatal Outcomes and Congenital Malformations in Children Born After Dydrogesterone Application in Progestin-Primed Ovarian Stimulation Protocol for IVF: A Retrospective Cohort Study. Drug Des Dev Ther (2019) 13:2553–63. 10.2147/dddt.S210228
    1. Zolfaroli I, Ferriol GA, Mora JH, Cano A. Impact of Progestin Ovarian Stimulation on Newborn Outcomes: A Meta-Analysis. J Assist Reprod Genet (2020) 37:1203–12. 10.1007/s10815-020-01755-0
    1. Evans MB, Parikh T, DeCherney AH, Csokmay JM, Healy MW, Hill MJ. Evaluation of the Cost-Effectiveness of Ovulation Suppression With Progestins Compared With GnRH Analogs in Assisted Reproduction Cycles. Reprod Biomed Online (2019) 38:691–8. 10.1016/j.rbmo.2018.12.044

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj